Given that endocytosis of flotillin-1 and flotillin-2 is regulated by Fyn kinase [87] its pharmacological inhibition may proof to be beneficial in treating progressive disease and particularly NASH. Here, FLOT1 is linked to metabolic dysfunction-associated steatohepatitis.